Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L. Levine, D. Gary Gilliland, Martha Wadleigh et al.|Cancer Cell|2005Cited by 3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Mehmet Asım Bilen et al.|The Lancet|2020Cited by 1.8k
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al.|Haematologica|2015Cited by 252
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al.|The Lancet|2023Cited by 181
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162